Galectin Therapeutics

1 follower


Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pat... Read more

Industries

Employees

11-50

Links

Org chart

Joel Lewis
CEO & President

Joel Lewis

Collapse
Susan Thornton
VP, Regulatory Affairs
Jeff Katstra
Head of CMC & Pharmaceutical Development
Marla Mills-Wilson
Executive Director, Clinical Operations

Board & advisors

Kevin D. Freeman
Vice Chairman
Gilbert F. Amelio
Independent Director
Kary Eldred
Independent Director
Gilbert S. Omenn
Independent Director
Marc Rubin
Independent Director
Elissa J. Schwartz
Independent Director
Richard A. Zordani
Independent Director